Tenax Therapeutics

NASDAQ: TENX ↗$14.53 USD~$50M (small-cap, July 2026) MCAP

#Pulmonary Hypertension (PH)#Heart Failure with Preserved Ejection Fraction (HFpEF)#Cardiogenic Shock #Cardiopulmonary Disease

Tenax Therapeutics is a specialty pharmaceutical company developing therapies for pulmonary hypertension and other cardiovascular diseases with high unmet medical need. Lead candidate TNX-103 (oral imatinib) is being developed for Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a large and underserved patient population. The company has historically advanced levosimendan (TNX-101) in cardiogenic shock and has presented TNX-103 data at the 2026 ESC Congress.

Company Info

Sector:Specialty Pharmaceuticals / Cardiopulmonary Disease

Headquarters:Chapel Hill, North Carolina, USA

Founded:2014

Website:www.tenaxthera.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and TNX-103 program update

Clinical Development Pipeline

TNX-103 (oral imatinib)

Target: Tyrosine kinase inhibitor (PDGFR pathway)

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TNX-101 (levosimendan)

Target: Calcium sensitizer and K-ATP channel activator

Cardiogenic shock and post-cardiac-surgery low cardiac output

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Christopher T. Giordano

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Chapel Hill, NC

Apply Now →